Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Immuneering
Biotech
Immuneering touts 64% survival, fueling race with Revolution
Immuneering reported updated data on atebimetinib in first-line pancreatic cancer, linking the MEK inhibitor to 64% overall survival at 12 months.
Nick Paul Taylor
Jan 8, 2026 5:17am
Immuneering sees 94% survival at 6 months in pancreatic cancer
Jun 17, 2025 10:55am
Ex-J&J research chief lands at FogPharma—Chutes & Ladders
Mar 31, 2023 9:30am
Immuneering stops neuroscience R&D, focuses on universal-RAS
Mar 7, 2023 6:30am
